Star anise, the unusual fruit of a small oriental tree, is sold in supermarkets in the UK to consumers seeking its pungent, liquorice-like flavour.
But the herb has a vital function as the source of shikimic acid from which the drug Tamiflu is made, the only defence the world currently has against the threatened flu pandemic.
Tamiflu cannot prevent infection with avian flu but it can reduce its severity. In the absence of an effective vaccine - which has not yet been developed - it is all that stands between the world and what could become a modern plague.
Yesterday it emerged that a shortage of star anise is one of the key reasons why countries including Britain cannot obtain enough Tamiflu to protect their populations. European Union ministers met yesterday to discuss measures to reduce contact between wild birds and poultry to curb its spread.
The deadly H5N1 strain of the virus, which has infected more than 100 humans, killing more than 60, in the Far East, was identified this week in poultry in Turkey. Results of tests on infected birds in Romania are expected to be revealed on Monday. EU scientistsagreed measures that could lead to millions of chickens and turkeys being kept indoors to prevent contact with migrating birds.
In Britain, the Animal Welfare minister Ben Bradshaw said that the Government had not ruled out ordering free-range poultry in Britain to be moved indoors.
As moves to halt the growing threat of avian flu intensified, governments sought to stockpile the only drug currently available to offer any sort of defence for humans. The herb from which Tamiflu is made is grown in four provinces in China and "huge quantities" of its seeds are needed, according to the Swiss pharmaceutical manufacturer Roche.
It is harvested by local farmers between March and May, purified and the shikimic acid extracted at the start of a 10-stage manufacturing process which takes a year.
Only star anise grown in the four provinces of China is suitable for manufacture into Tamiflu and 90 per cent of the harvest is already used by Roche.
The company has faced demands to relax the patent on the drug to allow other manufacturers to produce it.
Keith Taylor, of the Green Party, said: "Some countries have asked the World Health Organisation to pressure Roche into relinquishing the patent in order to allow a cheaper, generic version of the drug to be produced on a national level.
"The WHO refuses, citing Roche's donation of three million treatment courses as evidence that Roche is being responsible. This decision jeopardises millions of lives in the name of profit and is anything but responsible."
However, Roche responded by saying: "Because of the shortage of the raw material it would be very difficult for another manufacturer to set up production."
The UK Government has ordered 14.6 million courses of Tamiflu, enough for 25 per cent of the population, but only 2.5 million courses have so far been delivered. Other countries, including the United States, are behind the UK in the queue. Roche said it had doubled production of Tamiflu in 2004, doubled it again in 2005 and planned to double it again next year. But it said calls for the patent on the drug to be removed so that other companies could boost manufacturing capacity to meet the worldwide demand would not work.
The spokeswoman said: "It would take two to three years for another company to build the manufacturing capacity. The process is very complicated and the drug takes us 12 months to produce. Once you have built the facilities you have to get regulatory approval and the manufacturing licences.
"And then there is the shortage of the raw material."
Roche has developed a synthetic source of acidinic acid, made from the bacterium E Coli. Vast quantities of E Coli are mixed with glucose in vats the size of two buses. But star anise remains the chief source, the company said.
Once shikimic acid is extracted from the seeds of star anise it is converted to epoxide in a process requiring three chemical steps carried out at low temperature on seven separate sites.
The most dangerous part of the process involves the conversion of epoxide into azide in a reaction that produces highly explosive material. This is carried out by specialist companies that handle the material in small quantities to reduce the risk of explosion.
Currently only one US company and two European companies are approved by the drug regulatory authorities in America and Europe to carry out the process.
The final step involves the production of crystal strands of the active ingredient of Tamiflu, whose chemical name is oseltamivir, which are vacuum dried and converted to capsules.
The World Health Organisation yesterday declined to comment on reports that it was in negotiation with Roche over the lifting of the patent on Tamiflu.
"If we were in discussion with them it would be to relieve the supply shortage of the drug and to help poorer countries.
"But it would not be helpful to do that in public," a WHO spokesman said.
Join our new commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies